Background: The response definitions proposed by the European LeukemiaNet (ELN) have been recently modified. We evaluated the new criteria for de novo imatinib (400 mg/d) chronic phase chronic myeloid leukemia (CP-CML) pat...
3439Introduction: The European LeukemiaNet (ELN) recommendations for the management of chronic phase chronic myeloid leukemia (CP-CML) have provisionally defined criteria for suboptimal and failure to second-generation tyrosine kinase inhibitors (TKIs) (Baccarani et al., J Clin Oncol. 27 (35):6041...
Disease response was evaluated by the Investigators according to the clinico-hematological European LeukemiaNet (ELN) criteria [Barosi et al., Blood. 2009 ... A Rambaldi,A Iurlo,A Vannucchi,... - 《Blood》 被引量: 0发表: 2017年 Results from a phase I/II trial of cusatuzumab combined...
We have analyzed 399 chronic phase (CP) CML pts receiving first-line imatinib because they were found to meet one of the criteria for failure or suboptimal response. Overall, 45/166 (27.1%) failures were found to be positive for one or more BCR-ABL KD mutations. In particular, mutations ...